ArticlePloS one2026

Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.

XueYin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.